research update
-
Research updates, July 8
The biotech company Invivyd, which makes the COVID-19 monoclonal antibody Pemgarda, announced this week that it has launched the SPEAR Study Group to explore the drug for Long COVID and post-vaccine syndrome (PVS).
-
Research updates, July 1
Scientists found a new antiviral drug prototype that prevented Long COVID in mice and could also help treat the disease. In a study describing this milestone, published in Nature Communications, researchers stated the antiviral targets the coronavirus’ PLpro protein, as opposed to the Mpro protein, which Paxlovid targets.
-
Research updates, June 24
A new review paper published in Psychiatry and Clinical Neurosciences focuses on how Long COVID impacts the nervous and immune systems, and describes it as a neuroimmune condition.
-
Research updates, June 17
Pregnant people infected with SARS-CoV-2 during their first trimester were more likely to have smaller newborns, according to a new study in Pediatric Research.
-
Research updates, June 10
Three recent studies show the harmful effects of misdiagnosis for chronic diseases and conditions. The first, a meta-analysis in Psychological Bulletin of 151 studies encompassing 11 diseases (including Long COVID) and over 11,000 participants, found that medical gaslighting led to adverse impacts including diagnostic delay and emotional stress.
-
Research updates, June 3
A new National Institutes of Health RECOVER program study in JAMA Pediatrics found that around one in seven children under age six with a prior SARS-CoV-2 infection met the probable diagnostic criteria for Long COVID. Studying over 1,000 infants, toddlers, and preschool-aged children, researchers revealed differences in how Long COVID presented between age groups.
-
Research updates, May 27
A large study in Nature Genetics found a genetic risk factor for developing Long COVID. Researchers studied genetics data from 6,450 participants with Long COVID and over a million population controls across 16 countries, leading to the discovery that a variant near the FOXP4 gene increased the risk of the disease by about 60%.
-
Research updates, May 20
Early results from a Long COVID clinical trial assessing the monoclonal antibody AER002 found no difference between those who got the drug and placebo. Researcher Michael Peluso revealed the results at the PolyBio Spring Symposium; he and his colleagues are still analyzing data and will publish a paper later.
-
Live blog: Following the Spring 2025 PolyBio Symposium on Long COVID and related diseases
Leading scientists studying Long COVID and related chronic diseases are set to present updates to their work on Friday at the PolyBio Research Foundation’s Spring Symposium. The Sick Times’ team will be following the presentations throughout the day.
-
Research updates, May 13
The Bateman Horne Center and Open Medicine Foundation recently released a highly anticipated ME and Long COVID clinical care guide. The 96-page guide has been praised by many in the community as a useful tool for clinicians, patients, and their families.
Follow Us
get the latest long covid news
Trending
Recent ARTICLES
Tags
advocacy arts CDC clinical trials commentary COVID-19 precautions disability essay government policy H5N1 healthcare HHS influenza international Long COVID in children masks and respirators ME ME/CFS medical education national COVID-19 trends NIH NIH RECOVER podcast public health research update science Trump administration updates and events vaccines wastewater surveillance